You are here

LOXO-292

Racing Blueprint, Lilly drug gets priority review for RET hopeful

Fierce Biotech

Wed, 01/29/20 - 10:35 am

Blueprint Medicines

non-small cell lung cancer

Lilly's RET drug, nabbed in Loxo buyout, hits 68% ORR in lung cancer

Fierce Biotech

Mon, 09/9/19 - 10:21 am

non-small cell lung cancer

4 Biotech Stocks With Big Catalysts in September

Motley Fool

Thu, 09/5/19 - 10:14 pm

Mirati Therapeutics

Pralsetinibdicines

ASCO data for Blueprint's BLU-667 competitive with Lilly's LOXO-292 in RET-altered cancers

BioCentury

Mon, 06/3/19 - 11:25 am

Blueprint Medicines

RET-altered cancer

Cancer drug rivals at Loxo and Blueprint go toe-to-toe once again, and one analyst scores a (possible) win on points

Endpoints

Mon, 10/8/18 - 09:58 am

Blueprint Medicines

medullary thyroid cancer

FDA waves Loxo through for second ‘breakthrough’ in tissue-agnostic cancer therapy

Endpoints

Wed, 09/5/18 - 10:32 am

breakthrough status

Highly anticipated trial results expected soon could move all three of these biotechs

Motley Fool

Mon, 09/3/18 - 12:07 pm

Sangamo Therapeutics

Esperion Therapeutics

Loxo Unveils More Data, Paves a Path Forward In Precision Oncology

Xconomy

Sat, 06/2/18 - 11:31 am

clinical trials

Does a Blue Ribbon Make This Biotech Stock a Buy Now?

Motley Fool

Sat, 05/19/18 - 11:18 am

5 takeaways from the first look at cancer's biggest conference

Biopharma Dive

Thu, 05/17/18 - 10:44 pm

Bristol-Myers Squibb

Jounce Therapeutics